After two other liver disease projects fade into the background Ionis delays the antisense asset AKCEA-ANGPTL3-LRx by a year.
Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
Novo Nordisk’s first cardiovascular collaboration could lead to an antibody versus antisense showdown in dyslipidaemia.
Trailing the leaders in amyloidosis and Nash, the respective small caps Eidos and Conatus look to mid-stage trial readouts to demonstrate their relevance.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
The sellside’s protestations aside, results at the World Muscle meeting position risdiplam and AVXS-101 as serious challengers to Spinraza in spinal muscular atrophy.
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.